155
Participants
Start Date
February 28, 2001
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
interferon beta 1a 30 ug IM once weekly
Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
Jacobs Neurological Institute, Buffalo
University of Rochester, Rochester
Allegheny Neurological Associates, Pittsburgh
Univeristy of Pennsylvania Medical Center, Philadelphia
The Neurology Group, Norristown
Virginia Commonwealth University/Medical College of Virginia, Richmond
Neurological Associates, Inc., Richmond
Carolinas Medical Center - MS Center, Charlotte
MS Center of Atlanta, Atlanta
Jaeb Center for Health Research, Tampa
The Ohio State University, Columbus
Cleveland Clinic Foundation, Cleveland
Michigan State University, East Lansing
University of Iowa College of Medicine, Iowa City
Marshfield Clinic, Marshfield
Beta Research, Inc, Elk Grove
St. Louis University Health Sciences Center, St Louis
Univeristy of Texas Houston Health Science Center, Houston
MS Treatment Center at Griffin Hospital, Derby
Beth Israel Deaconess Medical Center, Boston
Vancouver Hospital Health Sciences Centre, Vancouver
QEII Health Sciences Centre, Halifax
Ottawa General Hospital, Ottawa
University of Toronto - St. Michael's Hospital, Toronto
Hospital Notre Dame, Montreal
Montreal Neurological Institute, Montreal
Collaborators (1)
Biogen
INDUSTRY
Beth Israel Deaconess Medical Center
OTHER